REFERENCES
1. Dobbs SM, Dobbs RJ, Weller C, et al. Peripheral aetiopathogenic drivers and mediators of Parkinson’s disease and co-morbidities: role of gastrointestinal microbiota. J Neurovirol 2016;22:22-32.
2. Tucker RM, Ryan S, Hayee BH, et al. Distinctive Pathophysiology Underlying Constipation in Parkinson’s Disease: Implications for Cognitive Inefficiency. J Clin Med 2020;9:1916.
3. Chen Y, Yu M, Liu X, et al. Clinical characteristics and peripheral T cell subsets in Parkinson’s disease patients with constipation. Int J Clin Exp Pathol 2015;8:2495-504.
4. Zhu F, Li C, Gong J, Zhu W, Gu L, Li N. The risk of Parkinson’s disease in inflammatory bowel disease: A systematic review and meta-analysis. Dig Liver Dis 2019;51:38-42.
5. Hui KY, Fernandez-Hernandez H, Hu J, et al. Functional variants in the
6. Bialecka M, Kurzawski M, Klodowska-Duda G, et al. CARD15 variants in patients with sporadic Parkinson’s disease. Neurosci Res 2007;57:473-6.
7. Ma Q, An X, Li Z, et al. P268S in NOD2 associates with susceptibility to Parkinson’s disease in Chinese population. Behav Brain Funct 2013;9:19.
8. Liu Z, Lee J, Krummey S, Lu W, Cai H, Lenardo MJ. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol 2011;12:1063-70.
9. Negroni A, Pierdomenico M, Cucchiara S, Stronati L. NOD2 and inflammation: current insights. J Inflamm Res 2018;11:49-60.
10. Tangye SG, Al-Herz W, Bousfiha A, et al. Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2020;40:24-64.
11. Lill CM, Roehr JT, McQueen MB, et al; 23andMe Genetic Epidemiology of Parkinson’s Disease Consortium., International Parkinson’s Disease Genomics Consortium., Parkinson’s Disease GWAS Consortium., Wellcome Trust Case Control Consortium 2). Comprehensive research synopsis and systematic meta-analyses in Parkinson’s disease genetics: the PDGene database. PLoS Genet 2012;8:e1002548.
12. The Oxford Centre for Evidence-Based Medicine (CEBM). OCEBM Levels of Evidence. Available from: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence. [Last accessed on 11 Jan 2021].
13. Tucker RM, Augustin AD, Hayee BH, et al. Role of
14. Dobbs SM, Charlett A, Dobbs RJ, et al. Antimicrobial surveillance in idiopathic parkinsonism: indication-specific improvement in hypokinesia following Helicobacter pylori eradication and non-specific effect of antimicrobials for other indications in worsening rigidity. Helicobacter 2013;18:187-96.
15. Augustin AD, Charlett A, Weller C, et al. Quantifying rigidity of Parkinson’s disease in relation to laxative treatment: a service evaluation. Br J Clin Pharmacol 2016;82:441-50.
16. Dobbs RJ, Charlett A, Dobbs SM, et al. Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study. Gut Pathog 2012;4:12.
17. Fasano A, Bove F, Gabrielli M, et al. The role of small intestinal bacterial overgrowth in Parkinson’s disease. Mov Disord 2013;28:1241-9.
18. Tan AH, Mahadeva S, Thalha AM, et al. Small intestinal bacterial overgrowth in Parkinson’s disease. Parkinsonism Relat Disord 2014;20:535-40.
19. Parada Venegas D, De la Fuente MK, Landskron G, et al. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front Immunol 2019;10:277.
20. Moher D, Shamseer L, Clarke M, et al; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
21. Schwiertz A, Spiegel J, Dillmann U, et al. Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson’s disease. Parkinsonism Relat Disord 2018;50:104-7.
22. Mulak A, Koszewicz M, Panek-Jeziorna M, Koziorowska-Gawron E, Budrewicz S. Fecal Calprotectin as a Marker of the Gut Immune System Activation Is Elevated in Parkinson’s Disease. Front Neurosci 2019;13:992.
23. Weis S, Schwiertz A, Unger MM, et al. Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota. NPJ Parkinsons Dis 2019;5:28.
24. Houser MC, Chang J, Factor SA, et al. Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson’s Disease. Mov Disord 2018;33:793-804.
25. Devos D, Lebouvier T, Lardeux B, et al. Colonic inflammation in Parkinson’s disease. Neurobiol Dis 2013;50:42-8.
26. Perez-Pardo P, Dodiya HB, Engen PA, et al. Role of TLR4 in the gut-brain axis in Parkinson’s disease: a translational study from men to mice. Gut 2019;68:829-43.
27. Davies KN, King D, Billington D, Barrett JA. Intestinal permeability and orocaecal transit time in elderly patients with Parkinson’s disease. Postgrad Med J 1996;72:164-7.
28. Forsyth CB, Shannon KM, Kordower JH, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease. PLoS One 2011;6:e28032.
29. Salat-Foix D, Tran K, Ranawaya R, Meddings J, Suchowersky O. Increased intestinal permeability and Parkinson disease patients: chicken or egg? Can J Neurol Sci 2012;39:185-8.
30. Clairembault T, Leclair-Visonneau L, Coron E, et al. Structural alterations of the intestinal epithelial barrier in Parkinson’s disease. Acta Neuropathol Commun 2015;3:12.
31. Loffredo L, Ettorre E, Zicari AM, et al; Neurodegenerative Disease study group. Oxidative Stress and Gut-Derived Lipopolysaccharides in Neurodegenerative Disease: Role of NOX2. Oxid Med Cell Longev 2020;2020:8630275.
32. Dufek M, Hamanová M, Lokaj J, et al. Serum inflammatory biomarkers in Parkinson’s disease. Parkinsonism Relat Disord 2009;15:318-20.
33. Hasegawa S, Goto S, Tsuji H, et al. Intestinal Dysbiosis and Lowered Serum Lipopolysaccharide-Binding Protein in Parkinson’s Disease. PLoS One 2015;10:e0142164.
34. Pal GD, Shaikh M, Forsyth CB, Ouyang B, Keshavarzian A, Shannon KM. Abnormal lipopolysaccharide binding protein as marker of gastrointestinal inflammation in Parkinson disease. Front Neurosci 2015;9:306.
35. Wijeyekoon RS, Kronenberg-Versteeg D, Scott KM, et al. Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson’s disease. Brain Behav Immun 2020;87:473-88.
36. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
38. Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol 2015;8:23-36.
39. Bjarnason I. The use of fecal calprotectin in inflammatory bowel disease. Gastroenterol Hepatol 2017;13:53-6.
40. Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis 2009;15:1746-54.
41. Joshi S, Lewis SJ, Creanor S, Ayling RM. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem 2010;47:259-63.
42. Musa MA, Kabir M, Hossain MI, et al. Measurement of intestinal permeability using lactulose and mannitol with conventional five hours and shortened two hours urine collection by two different methods: HPAE-PAD and LC-MSMS. PLoS One 2019;14:e0220397.
43. Riordan SM, McIver CJ, Thomas DH, Duncombe VM, Bolin TD, Thomas MC. Luminal bacteria and small-intestinal permeability. Scand J Gastroenterol 1997;32:556-63.
44. Fasano A. Zonulin, regulation of tight junctions, and autoimmune diseases. Ann N Y Acad Sci 2012;1258:25-33.
45. Ajamian M, Steer D, Rosella G, Gibson PR. Serum zonulin as a marker of intestinal mucosal barrier function: may not be what it seems. PLoS One 2019;14:e0210728.
46. Sina C, Kemper C, Derer S. The intestinal complement system in inflammatory bowel disease: Shaping intestinal barrier function. Semin Immunol 2018;37:66-73.
47. Sünderhauf A, Skibbe K, Preisker S, et al. Regulation of epithelial cell expressed C3 in the intestine - Relevance for the pathophysiology of inflammatory bowel disease? Mol Immunol 2017;90:227-38.
48. Luk GD, Bayless TM, Baylin SB. Diamine oxidase (histaminase). A circulating marker for rat intestinal mucosal maturation and integrity. J Clin Invest 1980;66:66-70.
49. Wolvekamp MC, de Bruin RW. Diamine oxidase: an overview of historical, biochemical and functional aspects. Dig Dis 1994;12:2-14.
50. Jha AK, Chaudhary M, Dayal VM, et al. Optimal cut-off value of fecal calprotectin for the evaluation of ulcerative colitis: An unsolved issue? JGH Open 2018;2:207-13.
51. Dobbs RJ, Dobbs SM, Weller C, et al. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism. Helicobacter 2005;10:267-75.
52. Chen H, O’Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson’s disease. Am J Epidemiol 2008;167:90-5.
53. Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 2005;57:168-75.
54. Ouchi Y, Yagi S, Yokokura M, Sakamoto M. Neuroinflammation in the living brain of Parkinson’s disease. Parkinsonism & Related Disorders 2009;15:S200-4.
55. Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol 2017;14:269-78.
56. Brenchley JM, Douek DC. Microbial translocation across the GI tract. Annu Rev Immunol 2012;30:149-73.
57. Unger MM, Spiegel J, Dillmann KU, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat Disord 2016;32:66-72.
58. Roager HM, Licht TR. Microbial tryptophan catabolites in health and disease. Nat Commun 2018;9:3294.
59. Neal MD, Leaphart C, Levy R, et al. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol 2006;176:3070-9.
60. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther 2017;2:17023.
61. Rocha Sobrinho HMD, Silva DJD, Gomides LF, Dorta ML, Oliveira MAP, Ribeiro-Dias F. TLR4 and TLR2 activation is differentially associated with age during Parkinson’s disease. Immunol Invest 2018;47:71-88.
62. Lau E, Marques C, Pestana D, et al. The role of I-FABP as a biomarker of intestinal barrier dysfunction driven by gut microbiota changes in obesity. Nutr Metab (Lond) 2016;13:31.
63. Sutherland L, Verhoef M, Wallace J, van Rosendaal G, Crutcher R, Meddings J. A simple, non-invasive marker of gastric damage: sucrose permeability. The Lancet 1994;343:998-1000.
64. Guardiola J, Lobatón T, Rodríguez-Alonso L, et al. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol 2014;12:1865-70.
65. Pajares M, I Rojo A, Manda G, Boscá L, Cuadrado A. Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications. Cells 2020;9:1687.
66. Poullis A, Foster R, Mendall MA, Shreeve D, Wiener K. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. Eur J Gastroenterol Hepatol 2003;15:573-4. author reply 574
